148214-90-8

Basic information

• Product Name: (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate
• Synonyms: TRANS-3-AMINO-1-BOC-4-HYDROXYPYRROLIDINE;1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester,(3R,4R)-rel-(9CI);(3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate;trans-3-Amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester;tert-butyl (trans)-3-amino-4-hydroxy-1-pyrrolidinecarboxylate(SALTDATA: HCl);(3R,4R)-1-Boc-3-aMino-4-hydroxypyrrolidine;tert-Butyl (3R,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate;(3R,4R)-rel-tert-Butyl 3-aMino-4-hydroxypyrrolidine-1-carboxylate
• CAS NO: 148214-90-8
• Molecular Formula: C9H18N2O3
• Molecular Weight: 202.25
• Product Categories: AMINOACID;pharmacetical
• Mol File: 148214-90-8.mol

Chemical Properties

• Boiling Point: 308.762 °C at 760 mmHg
• Flash Point: 140.535 °C
• Appearance: /
• Density: 1.179 g/cm³
• Vapor Pressure: 6.07E-05mmHg at 25°C
• Refractive Index: 1.517
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.36±0.40(Predicted)
• CAS DataBase Reference: (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate(148214-90-8)
• EPA Substance Registry System: (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate(148214-90-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 148214-90-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate is used as a research compound for its potential medicinal properties. It is studied for its ability to inhibit certain enzymes, which can be crucial in the development of new pharmaceuticals targeting specific diseases.
Used in Organic Synthesis:
In the field of organic synthesis, (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate is used as a key intermediate or building block in the synthesis of various organic compounds, including pharmaceuticals and other specialty chemicals.
Used in Drug Delivery Systems Development:
(3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate is used as a component in the development of innovative drug delivery systems. Its incorporation into these systems aims to improve the delivery, bioavailability, and therapeutic outcomes of various pharmaceutical agents.
Used in Enzyme Inhibition Studies:
In the study of enzyme inhibition, (3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate is used as a potential inhibitor of specific enzymes. This application is significant in the development of drugs that can modulate enzyme activity to treat various diseases.
Used in Medicinal Chemistry:
(3R,4R)-tert-Butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate is utilized in medicinal chemistry as a versatile compound for the design and synthesis of new pharmaceutical entities. Its unique structure and properties make it a valuable tool in the creation of novel therapeutic agents.

InChI:InChI=1/C9H18N2O3/c1-9(2,3)14-8(13)11-4-6(10)7(12)5-11/h6-7,12H,4-5,10H2,1-3H3/t6-,7-/m1/s1

Upstream product

• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 4248-19-5 tert-butyl carbazate 
• 1202067-33-1 (3S,4S)-3-azido-4-(trimethylsilanyloxy)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 183184-52-3 1-((3S,4S)-3-azido-4-hydroxypyrrolidin-1-yl)-2,2,2-trifluoroethan-1-one 
• 926913-20-4 (3R,4S)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 190792-74-6 (3S,4S)-4-amino-1-N-tert-butyloxycarbonyl-3-hydroxypyrrolidine 
• 926912-91-6 (3R,4R)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 1214272-54-4 (3R,4S)-cis-N-Boc-3-hydroxy-4-azidopyrrolidine 
• 203434-45-1 (±)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 1202067-36-4 (3R,4R)-3-azido-4-(trimethylsilanyloxy)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 926912-99-4 (3S,4R)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 1214272-52-2 (3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 

Downstream Products

• 1202067-41-1 (3aS,6aR)-2-phenyl-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 
• 1214272-56-6 (3S,4S)-trans-N-Boc-3-acetylthio-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1214272-57-7 (3S,4S)-trans-N-Boc-3-mercapto-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1214272-55-5 (3R,4S)-cis-N-Boc-3-hydroxy-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1174020-29-1 cis-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 138026-93-4 (trans)-tert-butyl hexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate 
• 859213-33-5 (3S,4S)-tert-butyl 3-(dimethyl amino)-4-hydroxypyrrolidine-1-carboxylate 
• 1215485-03-2 3,4-diaminopyrrolidinyl-1-carboxylic acid tert-butyl ester 
• 1215210-04-0 (3S,4S)-3-amino-4-hydroxypyrrolidine dihydrochloride 

Relevant articles and documents

Guanidine derivative and application thereof

The invention relates to a guanidine derivative serving as a VAP-1 inhibitor and application of the guanidine derivative, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be us

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS

The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of cancer and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), and more particularly compounds that modulate the function of IRAK4.

Tetrahydroisoquinoline compound and its preparation method, pharmaceutical composition and use

The invention relates to a tetrahydroisoquinoline compound and its preparation method, pharmaceutical composition and use. The tetrahydroisoquinoline compound is shown by the general formula (1). In the general formula (1), the symbols have the same definitions as in the specification.

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.

Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core

New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (～2 to 50 nM), MMP-13 (～2 to 50 nM), and MMP-14 (～4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, ～850 to >50 000 nM; MMP-7, ～4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

N -phosphonocarbonylpyrrolidine derivatives of guanine: A new class of Bi-substrate inhibitors of human purine nucleoside phosphorylase

A complete series of pyrrolidine nucleotides, (3R)- and (3S)-3-(guanin-9-yl)pyrrolidin-1-N-ylcarbonylphosphonic acids and (3S,4R)-, (3R,4S)-, (3S,4S)-, and (3R,4R)-4-(guanin-9-yl)-3-hydroxypyrrolidin-1-N- ylcarbonylphosphonic acids, were synthesized and e

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

Highly active organocatalysts for asymmetric anti-mannich reactions

Lighten the load! A family of enantiopure 4-oxy-substituted 3-aminopyrrolidines arising from the enantioselective ring-opening of meso-3-pyrroline oxide have been developed as catalysts for the asymmetric, anti-selective Mannich reaction (see scheme; PMP=